Summary Multiple primary tumours occurring in a three-year population-based series of patients with histopathologically peer-reviewed sarcomas from North West England were ascertained in order to look at the patterns of neoplasms seen. A total of 30 out of the 310 patients entered in the study had additional primary tumours. Very few patients were aged under 60 years at diagnosis of both their malignancies. The youngest was a known case of neurofibromatosis and, although seven patients were diagnosed with a sarcoma and carcinoma of the breast -a combination of cancers characteristic of the Li-Fraumeni cancer family syndrome -no other patients could directly be identified as suffering from any other cancer predisposition syndrome.
The occurrence of multiple primary cancers in an individual may happen by chance or may indicate that these neoplasms have shared aetiological risk factors or that treatment for one cancer may be directly related to the subsequent development of a second tumour. Alternatively, multiple primary cancers may be a result of genetic predisposition to malignancy in relation to conditions such as neurofibromatosis, Gorlin's syndrome, multiple endocrine neoplasia, Beckwith-Weidemann syndrome, or to various cancer family syndromes (Schottenfeld, 1982; Birch, 1987) . Sarcomas, in particular, are important components of at least two inherited cancer-prone conditions -neurofibromatosis (Hope & Mulvihill, 1981) and Li-Fraumeni syndrome (LFS) (Li et al., 1988) .
Studies have indicated that second primary tumours are diagnosed to excess in survivors of childhood sarcoma and that their occurrence may act as a marker for excesses of cancers characteristic of the LFS in close relatives (Strong et al., 1987; Burke et al., 1991) . A number of children and young adults with double primary neoplasms, including sarcomas, but without an apparent family history of LFS have also been shown to carry germ-line mutations in the p53 gene (Malkin et al., 1992; Toguchida et al., 1992) . Such mutations have been identified in a proportion of families with LFS (Malkin et al., 1990; Santibiafiez-Koref et al., 1991) .
The North West Sarcoma Incidence Study, which relates to a unique population-based series of patients of all ages with sarcoma, was established to look at the effects of histopathological peer-review, and at incidence and survival. Another important aim was to assess the patterns of multiple primary neoplasms occurring in these patients in relation to the presence of possible inherited predisposition to cancer in the population with a view to identifying families for further study.
Patients and methods
Patients eligible for the study were those diagnosed with sarcomas in the years 1982-84 inclusive who were resident in the North Western Regional Health Authority area at time of diagnosis and who were registered with the North Western Regional Cancer Registry (NWRCR). Sarcomas included in the study were those malignant soft tissue tumours (including those of visceral sites) given in the modified WHO scheme described by Enzinger and Weiss (1988) (Nwene & Smith, 1982) . Since patients with sarcomas may be referred to specialist centres for treatment and because of their high mortality, there is no reason to assume a registration level for sarcomas below the 95% level. Full details of ascertainment for the study are given elsewhere .
Histopathological material was requested for each case together with a copy of the original histology report. Sections were stained initially with haematoxylin and eosin and circulated to the five panel pathologists (each of whom had a special interest in sarcomas), together with a brief clinical summary of the case. Panel members recorded their diagnoses individually without discussion or knowledge of the original histology. Where there was any disagreement between members' diagnoses, the final (panel) diagnosis was arrived at by consensus and, if necessary, after the application of special stains including immunohistochemistry. A detailed description of the review method and special stains used has been reported . Final sarcoma diagnoses were coded using ICD-O (WHO, 1976 developed subsequent to a previously diagnosed tumour. Cases 19 and 24 each had other primary tumours diagnosed pre-and post-sarcoma. In six patients an additional primary tumour was diagnosed within six months of diagnosis of sarcoma. The most common sarcomas occurring as initial primary tumours were malignant fibrous histiocytoma (MFH) (7 cases) and leiomyosarcoma (three cases). The second malignancies in this group of patients included four carcinomas of respiratory tract, four of breast and three of gastro-intestinal tract. In the 16 patients diagnosed with a sarcoma subsequent to a previous tumour, there was a more diverse distribution of sarcoma sub-type. The initial tumours in these patients included a previous leiomyosarcoma of the uterus, seven other tumours of genito-urinary tract, three breast cancers, two colon cancers and two brain tumours. Additional primary tumours were diagnosed at ages ranging from 31-85 years.
The youngest patient in the study to be diagnosed with a sarcoma and an additional primary cancer (case 1) was known to suffer from neurofibromatosis. One patient had two sarcomas (case 10) and seven patients were diagnosed with carcinoma of the breast in addition to their sarcoma (cases 2, 6, 9, 11, 17, 18 and 29) .
A total of 261 patients (125 males and 136 females) and seven cancers were eligible to be included in analysis of risk of developing other malignancies after diagnosis of sarcoma. The observed cancers were in excess of those expected but the excess was not statistically significant (person years at risk = 807, obs = 7, exp = 4.58, RR = 1.5, 95% CI 0.6-3.1, P = 0.2). Analysis by sex, age at diagnosis (<60 years and 60 + years) and by histological sub-type of sarcoma similarly did not reveal any significant excesses of second cancers. Exclusion of second malignancies and years of follow-up within 6 months of diagnosis of sarcoma resulted in an excess risk of 1.06 (person years at risk = 692, obs = 4, exp = 3.77, 95% CI 0.3-2.7, P = 0.5).
Discussion
The study reveals that very few younger patients had multiple primary tumours involving sarcomas. Only two patients in the three-year series were under the age of 45 years, and six patients under the age of 60 years at the time of diagnosis of both their malignancies. The youngest case with a double primary cancer was a known case of neurofibromatosis but this syndrome, although registrable under cancer registration schemes, was not recorded on the registration form for any other patient in the study who developed a second primary tumour.
Ascertainment of patients with multiple primary cancers may lead to the identification of families with the LiFraumeni syndrome (LFS), a syndrome characterised by the development of sarcomas in children and young adults together with early onset cancers in their close relatives and in which multiple primary tumours frequently occur. Although seven patients in the series had a sarcoma and carcinoma of the breast, a classic combination of cancers in the LFS, only two of these patients were aged under 60 years, the age by which the majority of LFS cancers occur, at diagnosis of both tumours. There were no other obvious combinations of LFS-type cancers, e.g. sarcoma and brain tumour or sarcoma and leukaemia/lymphoma, in any younger patients and it seems unlikely that any other than a small proportion of the study population may have been affected by this syndrome. However, as more than 50 of the study population are still under the age of 60 years, a full family history of cancer for each patient would be necessary to define patients affected by the syndrome and who may be at risk of second malignancy.
It is clear that double primary cancers involving sarcomas are extremely rare in the general population and that few patients with syndromes predisposing to sarcomas and other cancers can be directly identified from cancer registrations. Many double primaries of this nature may simply be chance occurrences in patients of advancing age -data from this same population have shown that incidence of sarcomas in general increases with age to peak between 70-74 years .
As a result of the relatively small sample size, short mean period of follow up and high mortality resulting from sarcoma (Hartley et al., 1992) , ability to assess risk of developing a further malignancy after diagnosis of sarcoma is limited. However, the establishment of a unique populationbased series of sarcomas clearly defined by histopathological review is an important resource for further studies. Peer review is an essential pre-requisite for any investigation of this kind as reclassification of sarcomas is a consistent occurrence (Presant et al., 1986; Harris et al., 1991) . Follow-up of the study cohort via the NWRCR and NHSCR over a period of time will enable assessment of risk of subsequent cancer and will also identify those patients with early onset double primaries who may then form the subjects of further work on genetic predisposition to cancer.
